In this review, we will discuss ATR inhibitors, Polθ inhibitors and WRN inhibition as potential treatments for cancer and highlight how lessons from the discovery and development of PARPi and the study of PARPi resistance could inform the clinical development and use of new DDR inhibitors. The gene discussed is WRN; the disease is cancer.